Interferon α-targeted therapy

Research output: Contribution to journalArticle

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components. Although many of therapies have shown great efficacy, they often associate with adverse effects. The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE. The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE. Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE. Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE. There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor. The safety and dose-proportional pharmacokinetics of those agents were demonstrated. A larger study is currently ongoing, further safety profile will be evaluated. This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalUnknown Journal
Volume36
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Systemic Lupus Erythematosus
Interferons
Therapy
Safety
Autoantibodies
Cytokines
Monoclonal Antibody
Signaling Pathways
Pharmacokinetics
Therapeutics
Polymorphism
Clinical Trials
Receptor
Efficacy
Interferon alpha-beta Receptor
Dose
Pathway
Drugs
Update
Directly proportional

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Interferon α-targeted therapy. / Hanaoka, Hironari; Takeuchi, Tsutomu.

In: Unknown Journal, Vol. 36, No. 4, 2013, p. 181-188.

Research output: Contribution to journalArticle

@article{040ba46b6acc446a8898e81b6f1a9a0c,
title = "Interferon α-targeted therapy",
abstract = "Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components. Although many of therapies have shown great efficacy, they often associate with adverse effects. The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE. The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE. Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE. Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE. There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor. The safety and dose-proportional pharmacokinetics of those agents were demonstrated. A larger study is currently ongoing, further safety profile will be evaluated. This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.",
author = "Hironari Hanaoka and Tsutomu Takeuchi",
year = "2013",
doi = "10.2177/jsci.36.181",
language = "English",
volume = "36",
pages = "181--188",
journal = "Mathematical Social Sciences",
issn = "0165-4896",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Interferon α-targeted therapy

AU - Hanaoka, Hironari

AU - Takeuchi, Tsutomu

PY - 2013

Y1 - 2013

N2 - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components. Although many of therapies have shown great efficacy, they often associate with adverse effects. The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE. The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE. Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE. Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE. There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor. The safety and dose-proportional pharmacokinetics of those agents were demonstrated. A larger study is currently ongoing, further safety profile will be evaluated. This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.

AB - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components. Although many of therapies have shown great efficacy, they often associate with adverse effects. The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE. The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE. Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE. Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE. There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor. The safety and dose-proportional pharmacokinetics of those agents were demonstrated. A larger study is currently ongoing, further safety profile will be evaluated. This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.

UR - http://www.scopus.com/inward/record.url?scp=84883347025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883347025&partnerID=8YFLogxK

U2 - 10.2177/jsci.36.181

DO - 10.2177/jsci.36.181

M3 - Article

VL - 36

SP - 181

EP - 188

JO - Mathematical Social Sciences

JF - Mathematical Social Sciences

SN - 0165-4896

IS - 4

ER -